 Gilead Sciences Inc won US approval Friday to begin selling the first pill that promises to cure most hepatitis C patients without requiring other medicines but its near  cost will likely further inflame tensions between drug companies and health insurers over spiraling prices The drug dubbed Harvoni builds on Gileads blockbuster Sovaldi treatment which recorded the biggest drug launch in history after going on sale late last year and is itself a lightning rod for critics of drug prices 